Pyxis Oncology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $1.97 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.68, a 132.23% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.46.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $5.10, a 64.29% decline from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $14.28, a 4.77% increase from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $13.63, a 147.37% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $5.51.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.97 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $5.10 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $4.01 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $3.70 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $14.28 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $14.28 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $15.96 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $12.68 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $13.63 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $11.80 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $5.46 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $5.46 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $5.51 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $2.18 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $5.34 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |